Aniracetam is a fat-soluble nootropic compound of the racetam family, developed by the Swiss pharmaceutical company Hoffman-La Roche in the 1970s. Unlike the prototype racetam piracetam (which is water-soluble), aniracetam's lipophilicity requires consumption with dietary fat for absorption and confers it a somewhat broader pharmacological profile. It is most notable for its dual properties: cognitive enhancement through AMPA receptor potentiation, and anxiolytic effects through modulation of dopaminergic and serotonergic neurotransmission and GABA receptor activity. This combination — cognitive enhancement with mood and anxiety modulation — distinguishes aniracetam from more purely cognitive-focused racetams.
Aniracetam's primary mechanism is positive allosteric modulation of AMPA-type ionotropic glutamate receptors, which are central to synaptic plasticity, learning, and memory. By slowing the desensitization of these receptors, aniracetam prolongs excitatory transmission at the synapse, potentially enhancing long-term potentiation — the molecular correlate of learning. Community experience broadly supports a cognitive effect that is qualitatively different from stimulants: users describe enhanced verbal fluency, more fluid associative thinking, and easier access to articulate speech and complex ideas, without the jitteriness or motivational quality of stimulants.
The evidence base for aniracetam's efficacy in healthy adults is limited. Most controlled trials have been conducted in elderly patients with cognitive impairment, where improvements have been observed. Whether these findings translate to healthy individuals seeking cognitive enhancement is unresolved, though the compound has a strong following in nootropic communities. Aniracetam is approved as a prescription drug in several European countries and Japan, but is sold as an unregulated supplement in the United States and UK.